23 completed, 6 withdrawn, 5 recruiting, 5 unknown. 17 Not applicable, 9 Phase 1, 6 Phase 4, 4 Phase 2, 1 Phase 3.
Follow Opioid Overdose: new trials by email Literature Review of Opioid Overdose trials Research Report on Opioid Overdose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naloxone for Opioid Associated Out of Hospital Cardiac Arrest Naloxone 2 MG, Saline 2ml - Heart Arrest, Out-Of-Hospital, Opioid Overdose | Phase 2 | Not yet recruiting | University of California, San Francisco | 98 | 2027-03-01 | 2026-09-11 |
| Evaluation of Clinical Decision Support in Opioid Tapering Observational study without a prospective intervention - Medication Abuse, Harm Reduction | Not yet recruiting | University of Colorado, Denver | 200000 | 2026-11-01 | 2026-09-30 | |
| A Bundled Intervention to End Opioid Overdoses Bundled intervention (Experimental), control group, Buprenorphine (Experimental) - Opioid Use Disorder, Opioid Overdose | Phase 4 | Recruiting | University of Alabama at Birmingham | 160 | 2026-09-07 | 2026-10-02 |
| Pharmacokinetic (PK) Evaluation of Nalmefene Formulations Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection - Opioid Overdose | Phase 1 | Completed | Knoa Pharma LLC | 13 | 2026-02-06 | 2026-06-05 |
| Serious Game to Teach Opioid Overdose Response Serious game training - Opioid Overdose | Phase 2 | Not yet recruiting | University of Nevada, Reno | 850 | 2026-02-01 | 2024-12-11 |
| UnityPhilly Response App for Overdose Reversal UnityPhilly app - Opioid Overdose | Not applicable | Recruiting | Drexel University | 450 | 2025-09-16 | 2026-07-20 |
| A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose Naloxone-responder: A volunteer first responder system connected to emergency dispatch service and alerting overdose and first aid educated volunteers with naloxone to suspected opioid overdoses - Opioid Overdose | Not applicable | Recruiting | Region Skane | 1000 | 2025-09-01 | 2025-12-17 |
| Quantitative Xylazine Measurement in ED Opioid Overdose, Substance Use Disorders | Completed | Icahn School of Medicine at Mount Sinai | 75 | 2025-04-01 | 2026-03-25 | |
| Machine-Learning Prediction and Reducing Overdoses With EHR Nudges EHR-Embedded Elevated-Risk Flag, EHR-Embedded Elevated-Risk Flag with Behavioral Nudges, Usual Care - Opioid Overdose, Opioid Use | Not applicable | Active not recruiting | University of Pittsburgh | 1350 | 2025-03-10 | 2026-10-06 |
| A Bundled Intervention a bundled intervention, control group - Opioid Use Disorder, Opioid Overdose | Phase 1 / Phase 2 | Recruiting | University of Alabama at Birmingham | 190 | 2025-02-13 | 2026-02-23 |
| Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Nalmefene Injection, Naloxone Injection - Opioid Overdose, Opiate Overdose | Phase 3 | Withdrawn | University of New Mexico | 2024-08-26 | 2025-02-10 | |
| Blood Naloxone Levels Following Intradermal Injection in Humans intradermal naloxone, microneedle injection - Opioid Overdose | Phase 4 | Withdrawn | Johns Hopkins University | 2024-08-01 | 2024-11-01 | |
| Clinical Decision Support to Improve System Naloxone Co-prescribing Naloxone Co-prescribing Clinical Decision Support (CDS) - Medication Abuse, Harm Reduction | Completed | University of Colorado, Denver | 114272 | 2024-07-01 | 2026-09-29 | |
| Vending Machine Naloxone Distribution for Your Community (VENDY) VENDY - Harm Reduction, Naloxone | Phase 4 | Active not recruiting | University of Colorado, Denver | 4000 | 2024-06-01 | 2026-06-02 |
| Opioid Rapid Response System: Naloxone Training in Communities Opioid Rapid Resonse System (ORRS) training, Non-active opioid overdose response training - Opioid Overdose | Not applicable | Completed | University of Missouri-Columbia | 773 | 2024-05-24 | 2026-08-19 |
| Improving Availability of Intranasal Naloxone Enhanced Overdose Education (EOE), Standard education - Opioid Overdose | Not applicable | Unknown | Hartford Hospital | 84 | 2024-03-01 | 2024-06-07 |
| Safety, Tolerability, and Pharmacokinetics of CSX-1004 CSX-1004, Placebo - Opioid Overdose, Opioid Use Disorder | Phase 1 | Completed | Cessation Therapeutics, Inc. | 32 | 2023-08-01 | 2024-08-21 |
| Clinical Outcomes From Nalmefene Nalmefene Hydrochloride Injection, Naloxone Hydrochloride Injection - Opioid Overdose | Phase 4 | Withdrawn | Purdue Pharma LP | 2023-06-01 | 2023-07-12 | |
| Tailoring Overdose Education for Black Churches COEST - Opioid Overdose | Not applicable | Withdrawn | New York State Psychiatric Institute | 2023-04-01 | 2026-04-02 | |
| Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD No intervention, observational retrospective study - Opioid Use Disorder, Opioid Overdose | Active not recruiting | Kaiser Permanente | 27257 | 2023-03-29 | 2024-10-17 |
Showing 20 of 46. Sign in to see all of them.
Opiate Overdose (46) · Opioid-Related Disorders (10) · Drug Overdose (7) · Substance-Related Disorders (6) · Harm Reduction (5) · Death (2) · Emergencies (2) · Respiratory Insufficiency (2) · Chemically-Induced Disorders (1) · Hypoventilation (1) · Out-of-Hospital Cardiac Arrest (1) · Pain (1) · Pain, Postoperative (1)
Drug Misuse (46) · Mental Disorders (46) · Narcotic-Related Disorders (46) · Prescription Drug Misuse (46) · Chemically-Induced Disorders (45) · Substance-Related Disorders (40) · Drug Overdose (39) · Opioid-Related Disorders (36) · Pathological Conditions, Signs and Symptoms (6) · Behavior (5) · Pathologic Processes (5) · Disease Attributes (2) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Signs and Symptoms (2)
Naloxone (8) · nalmefene (5) · Buprenorphine (2) · Buprenorphine, Naloxone Drug Combination (2) · Control Groups (2) · Therapeutics (2) · Analgesics, Opioid (1) · Community-Institutional Relations (1) · Health Resources (1) · Injections (1) · Interviews as Topic (1) · Magnesium Chloride (1) · Observation (1) · Organizations (1) · Psychotherapy, Group (1)
New York State Psychiatric Institute (3) · University of Colorado, Denver (3) · Brown University (2) · Purdue Pharma LP (2) · University of Alabama at Birmingham (2) · Auburn University (1) · BC Centre on Substance Use (1) · Cessation Therapeutics, Inc. (1) · Drexel University (1) · Emergent BioSolutions (1) · Hartford Hospital (1) · Icahn School of Medicine at Mount Sinai (1) · Johns Hopkins University (1) · Kaiser Permanente (1) · King's College London (1)
United States (34) · Canada (4) · Sweden (2) · Denmark (1) · Egypt (1) · Jordan (1) · United Kingdom (1)
Brandon DL Marshall, PhD (2) · Li Li, MD;PhD (2) · Aaron Orkin, MD (1) · Abdullah Hiyari, MD (1) · Anh P Nguyen, PhD (1) · Barrot Lambdin, PhD, MPH (1) · Caitlin Bonney, MD (1) · Carol Strike, PhD (1) · Hye Jeong Choi (1) · Ingela Danielsson, MD (1) · Ingrid A Binswanger, MD (1) · Jacob Brenner, MD/PhD (1) · James R Langabeer, PhD (1) · Janice Faulknor, MD, CCFP (1)
PMID 29436397, PMID 33243291, PMID 34301246, PMID 34729851, PMID 35212639, PMID 35296414, PMID 35386013, PMID 35709575, PMID 36047381, PMID 36746325, PMID 37496452, PMID 37612698, PMID 37737966, PMID 38419058, PMID 39288373, PMID 39909302, PMID 40839512, PMID 41649817, PMID 42081274, PMID 42332351, PMID 42365998, PMID 42438068
R61DA057610 (2), 3UG1DA013727-20S5 (1), R01DA030351 (1), R01DA035207 (1), R01DA044985 (1), R01DA046620 (1), R01DA046867 (1), R01DA047975 (1), R25DA058490 (1), R33DA062351 (1), R41DA047779 (1), R61DA062351 (1)